NK-92® Cell Based Bioanalytical Solutions
are the Key to Optimizing R&D and Commercial Product
Development Efforts for Monoclonal Antibodies, Bi-Specifics and
Related Biological Products
Brink Biologics, Inc., a NantKwest, Inc. (Nasdaq:NK)
affiliate who serves as exclusively-licensed distributor of
NantKwest’s proprietary NK-92® natural killer cells, offers a
variety of research grade aNK™ and haNK® cell lines for
non-clinical laboratory use in discovery, translational and
developmental research and lot release testing for commercial
products ranging from monoclonal antibodies, bi-specific biologics,
cytokines and other bioactive products.
Using living cells for functional assays such as ADCC, ADCVI and
Cytokine Release Assays approximates closely what one would see in
live animal models. Through the use of NK-92® natural killer cells
in these assays, assay variability and unreliability are minimized.
For this reason, NK-92® cells are rapidly becoming the preferred
next-generation bioanalytical testing solution among large pharma
commercial developers, biosimilar developers, medical research
institutions, universities and the global research community.
Through a limited arrangement, Brink Biologics is pleased to
announce that the company has non-exclusively licensed its next
generation bioanalytical testing solution to Worcester
Polytechnic Institute (WPI). The terms of the agreement are not
disclosed.
Jeannine Coburn, PhD, assistant professor of biomedical
engineering at Worcester Polytechnic Institute, will use the cells
in her research into the development of clinically translatable
drug delivery strategies and three-dimensional
in vitro human disease models using
biologically-derived biomaterials.
“This agreement demonstrates the respect that research
institutions have for NantKwest’s proprietary rights in its
innovative cell lines and foundational technologies. Every
laboratory should get its NK-92® cells from Brink Biologics, which
is the only licensed commercial and research distributor of genuine
NK-92®,” said Mark Kokes, Chief Intellectual Property Officer of
NantWorks, LLC, supporting Brink Biologics and NantKwest.
Patrick Soon-Shiong, MD, Chairman and CEO of NantKwest added,
“With over 200 publications citing the use of NantKwest’s NK-92®
cells, the unique, enabling and proprietary characteristics of
these novel natural killer cells are well established. NK-92®
cell-supported assays have become the trusted and increasingly
popular choice of large pharma and biotech companies for their
growing antibody development programs and commercial product
release testing.”
Dr. Soon-Shiong continued, “These novel and proprietary cells
form the foundation for NantKwest’s clinical-stage aNK™, haNK®, and
t-haNK™ natural killer cell-based therapeutics programs and,
through Brink Biologics’ offering, they also represent a unique,
next generation bioanalytical testing solution. We are therefore
very pleased to announce this license agreement with Worcester
Polytechnic Institute.”
About Brink Biologics
Brink Biologics, Inc. (BBI) is a NantKwest, Inc. (NASDAQ: NK)
affiliated next-generation bioanalytical testing solutions company
located in the prestigious Torrey Pines biotechnology science park
in San Diego, CA. NK-92® cells, aNK™ and haNK® cells are natural
killer cell lines originating from a singular source, established
in stable cultures under GLP & cGMP conditions and further
modified and assembled into distinct panels of cell-lines, suitable
for a range of laboratory testing applications. These Neukopanel®
Cell Lines include CD16 expressing NK-92® cell lines, providing for
the first time the means to establish a consistent, robust, and
reliable assay for assessment of ADCC activity.
NEUKOPANEL is a trademark of Brink Biologics, Inc.
For additional information and licensing inquiries, please visit
www.brinkbiologics.com.
About NantKwest Inc.
NantKwest, a member of the NantWorks ecosystem of companies, is
an innovative clinical-stage immunotherapy company focused on
harnessing the power of the innate immune system by using the
natural killer cell to treat cancer and virally induced infectious
diseases.
NantKwest is uniquely positioned to implement precision cancer
medicine, with the potential to change the current paradigm of
cancer care. Natural Killer (NK) cells are a safeguard in the human
body designed to recognize and detect cells under stress due to
cancer or viral infection. NantKwest’s “off-the-shelf” activated NK
cell platform is designed to destroy cancer and virally infected
cells from the body. The safety of our NK cells as well as their
activity against a broad range of cancers have been tested in phase
I clinical trials in Canada and Europe as well as in multiple phase
I and II clinical trials in the United States. In addition to being
a universal cell-based therapy that does not require individualized
patient sourcing or matching, our NK cell products have been
largely administered in the outpatient setting as an
“off-the-shelf” living drug.
With the capacity to grow active killer cells as a living cancer
therapy, our NK cells have been designed to induce cell death
against cancers and virally infected cells by several mechanisms,
including: (i) innate killing, whereby all of our NK platforms
recognize the stress proteins typically found on cancer cells,
which, upon binding, release toxic granules to immediately kill
their targets; (ii) antibody-mediated killing with our haNK®
platform, which are NK cells engineered to express antibody
receptors that can bind to therapeutic antibody products, thereby
enhancing the cancer cell killing effect of that antibody; and
(iii) Chimeric Antigen Receptor directed killing using the taNK®
platform, which includes NK cells engineered to incorporate
chimeric antigen receptors (CARs) to target tumor-specific antigens
found on the surface of cancer cells. All three modes of killing
(innate, antibody-mediated, and CAR directed killing) are employed
by our t-haNK™ platform, which is an innovative combination of our
aNK, haNK® and taNK® platforms in a single product.
Our haNK®, and t-haNK™ platforms have been designed to address
certain limitations of CAR T-cell therapy including the capability
to infuse cell therapy in an outpatient setting which allows for
potential reduction of risk for serious cytokine storms and
protracted serious adverse events. In Phase I and II clinical
trials in patients with late stage cancer, our NK cells have been
administered as an investigational outpatient infusion safely with
greater than 300 infusions to date at a dose of 2 billion cells per
infusion.
By leveraging an integrated and extensive genomics and
transcriptomics discovery and development engine, together with a
pipeline of multiple, clinical-stage, immuno-oncology programs, we
believe NantKwest is uniquely positioned to be the premier
immunotherapy company and transform medicine by delivering living
drugs in a bag and bringing novel NK cell-based therapies to
routine clinical care.
NK-92, aNK, haNK, taNK, and t-haNK are trademarks of NantKwest,
Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include statements concerning or
implying the Company will be successful in improving the treatment
of cancer. Risks and uncertainties related to this endeavor
include, but are not limited to, obtaining FDA approval of our NK
cells as well as other therapeutics as part of the NANT Cancer
Vaccine platform as a cancer treatment.
Forward-looking statements are based on management's current
expectations and are subject to various risks and uncertainties
that could cause actual results to differ materially and adversely
from those expressed or implied by such forward-looking statements.
Accordingly, these forward-looking statements do not constitute
guarantees of future performance, and you are cautioned not to
place undue reliance on these forward-looking statements.
These and other risks regarding our business are described in
detail in our Securities and Exchange Commission filings, including
in our Annual Report on Form 10-K for the year ended December 31,
2018. These forward-looking statements speak only as of the date
hereof, and we disclaim any obligation to update these statements
except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190501005398/en/
Media Contact:Jen
Hodson562-397-3639jhodson@nantworks.com
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Aug 2024 to Sep 2024
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Sep 2023 to Sep 2024